Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer SUZHOU, China, Feb. 6, 2025 /PRNewswire/ — Alphamab Oncology (Stock Code: 9966.HK)… February 6, 2025
Explore the Challenges and Opportunities Faced by Businesses in the Digital Age of Innovation Thailand’s tourism sector thrives on natural attractions, but business leaders like Kriangkrai… February 6, 2025